Credits: Instagram
Birthdays are exciting for everyone. There's celebration, a cake, and balloons. But what if it goes wrong? This is what happened with Giang Pham, from Vietnam, who was celebrating her 33rd birthday on February 14, when a hydrogen balloon in her hand touched the flame from the candle on the cake and exploded on her face.
This incident was also captured on camera. The footage clearly shows how the balloon blew up as soon as it touched the flame. Her friends were shocked and can be heard gasping in the background as they saw this.
In the days following the incident, she also shared photos on her Instagram showing her bandaged face, and revealed the first-degree burns on her hand and second-degree burns on her face. However, the good news was that her vision was unaffected, though for her face to recover, it would take months.
She is now also warning others about the risks of using highly inflammable hydrogen balloons. The other alternative could be a helium balloon, which you could fly higher and they remain on the ceiling.
She revealed that her doctor estimated up to six months for her skin to recover. She would still have to go to the hospital for dressing and treatment. Another such case happened with a woman named Tine from Australia, when on her son's 7th birthday, the balloon exploded and "shook her house". Her son was burned in the forearm.
Such incidents happen because decorators want to save the cost by replacing helium with hydrogen, which is highly inflammable.
Giang shared that she experienced second-degree burn on her face and first-degree burn on her hands. As per John Hopkins Medicine, first degree burns affect only the epidermis, or the outer layer of skin. The burn site becomes red, painful, dry, however, there are no blisters. A mild sunburn could be an example of such a burn. This is also called superficial burns.
Whereas, second degree burns involve the epidermis and part of the dermis layer of the skin. The burn site appears red, blistered and could also be swollen and painful. This is also known as partial thickness burn.
Then comes the third degree burns, also known as full thickness burn. This destroys the epidermis and dermis and could also damage the underlying bones, muscles, and tendons. However, when the bones and muscles are burned, it could be referred to as a fourth degree burn. The burn sit appears white or charred and there is no feeling in the area since the nerve endings are destroyed.
The right way to treat a burn depends on its depth and how much of the body it covers. While minor, superficial burns can be managed at home, deeper or larger burns may need medical attention. Keep these essential guidelines in mind:
Knowing these simple steps can make a big difference in burn care and healing.
Credit: Canva
Three British Airways cabin members were taken to the hospital after they ate marijuana-laced sweets handed to them by a passenger during a flight from London Heathrow to Los Angeles.
The staffers were unaware that the sweets contained up to 300mg of THC, the main psychoactive compound in weed a produces the psychoactive effect.
The affected members are said to have had 'out-of-body experiences' after unknowingly consuming the weed-laced gummies. The airline has now launched an investigation to find the passenger who gave the crew member the marijuana edibles.
"It is a godsend in this case the sweets in question were not shared out among the crew until they had arrived in the US," one source told The Sun.
"They were consumed in the crew bus after touchdown, and tired staff gratefully gobbled them up. Almost immediately BA staff realized something was wrong.
"By the time the group had reached the crew hotel, three staff members who had numerous sweets began suffering 'out-of-body' experiences. They felt totally out of control and became panicked and scared."
As a result, the entire crew had to be grounded in LA and a new team was out in place to operate the return service. The affected members were flown back on a separate service days later as passengers.
THC is essentially the compound that causes the euphoric “high” associated with cannabis. It’s commonly consumed through smoking cannabis, edibles, tinctures, and capsules. THC also offers medical benefits but is more likely to cause psychoactive side effects.
Known for helping with nausea, appetite stimulation, chronic pain, and insomnia, this FDA-approved edible is used in synthetic forms (like dronabinol) for treating chemotherapy-induced nausea and appetite loss in conditions like AIDS.
THC can cause temporary effects like dry mouth, red eyes and increased heart rate. Long-term use, especially in adolescents, may be linked to psychiatric issues such as anxiety or low motivation.
While CBD is not intoxicating but has mild psychoactive properties, such as promoting relaxation, THC, however, directly binds to brain receptors, causing euphoria or a “high.
Furthermore, THC disrupts normal brain function, affecting memory, learning, and attention, especially in developing adolescent brains. It can cause acute panic, anxiety, and, in some cases, induce psychosis.
Along with this, it impairs coordination, slows reaction time, and alters judgment, directly contributing to motor-vehicle accidents.
Frequent use of marijuana has been previously linked to a higher risk of developing schizophrenia or other psychoses in people who are predisposed to these conditions.
According to the American Health Association, smoking cannabis also causes respiratory issues such as lung irritation and coughing as well as increases heart rate and blood pressure, which can raise the risk of heart attacks or strokes.
Credits: Canva
Erythritol sweetener, commonly found in most of the food we consume, whether it is a protein bar or energy drink could be linked to stroke risk. While it is considered as a safer alternative to sugar as a natural sweetener, a study from the University of Colorado suggests it could damage cells in the blood-brain barrier.
The blood-brain barrier is brain's security system that keeps the harmful substance off the limits, while letting in nutrients. Research also suggests that it would lead to serious consequences for heart health and stroke risk.
In the latest study, researchers exposed cells that form the blood–brain barrier to erythritol levels typically seen after consuming a soft drink sweetened with the compound. What followed was a cascade of cellular damage that could leave the brain more vulnerable to blood clots, one of the leading causes of stroke.
The researchers found that erythritol triggered intense oxidative stress, overwhelming cells with unstable molecules known as free radicals. At the same time, it weakened the body’s natural antioxidant defences. This double hit impaired normal cell function and, in some cases, led to cell death.
Damage to blood–brain barrier cells is particularly concerning because this barrier plays a crucial role in protecting the brain from harmful substances circulating in the bloodstream. When its integrity is compromised, the risk of neurological injury rises sharply.
Even more troubling was erythritol’s effect on how blood vessels regulate blood flow. Healthy blood vessels constantly adjust their width—expanding when organs need more oxygen and nutrients, and narrowing when demand is lower.
This process depends on a delicate balance between two molecules: nitric oxide, which relaxes blood vessels, and endothelin-1, which causes them to constrict. The study found that erythritol disrupted this balance by reducing nitric oxide production while increasing endothelin-1 levels.
The result is blood vessels that stay constricted longer than they should, potentially restricting blood flow to the brain. This kind of dysfunction is a known warning sign for ischaemic stroke, the most common form of stroke caused by blocked blood vessels.
The most alarming finding in the study was how body's natural protect against blood clot is disturbed. Under normal circumstances, cells release a substance called tissue plasminogen activator, which is described as a natural 'clot buster', which helps dissolve clots before they become dangerous. However, erythritol could interfere with this protective mechanism and allow clots to persist and cause damage.
Several have shown that people with higher blood levels of erythritol face significantly increased risks of cardiovascular events. In one major study, individuals with the highest erythritol levels were nearly twice as likely to suffer a heart attack or stroke.
However, researchers caution that the experiments were conducted on isolated cells rather than full blood vessels. More advanced models that better replicate human physiology will be needed to confirm the findings.
Erythritol occupies a unique space in the sweetener world. Classified as a sugar alcohol rather than an artificial sweetener, it escaped recent World Health Organization guidance discouraging artificial sweeteners for weight control. Its sugar-like taste has also made it a favorite in “keto-friendly” and sugar-free foods.
Credits: Canva
FDA refuses to review Moderna's flu vaccine: The U.S. Food and Drug Administration (FDA) has declined to begin reviewing Moderna’s application for its experimental flu vaccine. The company made the announcement on Tuesday. The decision marks another signal of stricter vaccine oversight under the Trump administration and has already rattled investor confidence, with Moderna’s stock falling nearly 7% in after-hours trading.
Read: CDC Vaccine Schedule: Coverage Falls From 17 to 11 Diseases For Children
Moderna said the FDA’s refusal came as a surprise and contradicted feedback the company had received earlier, before it submitted the application and launched phase three trials for the vaccine, known as mRNA-1010. The company has now requested a meeting with the agency to better understand what it described as an unclear “path forward.”
According to Moderna, the FDA did not flag any safety or efficacy concerns with the vaccine itself. Instead, the agency objected to the design of the clinical trial—despite having previously signed off on it. Moderna added that the setback would not affect its financial guidance for 2026.
The experimental flu shot had shown encouraging results in phase three trials last year, successfully meeting all primary trial endpoints. At the time, Moderna positioned the stand-alone flu vaccine as a critical step toward developing a combined influenza and COVID-19 vaccine, a key long-term goal for the company.
The decision comes amid sweeping changes to U.S. immunisation policy over the past year under Health and Human Services Secretary Robert F. Kennedy Jr., who has long expressed skepticism toward vaccines. Moderna on Tuesday pointed to the FDA’s top vaccine regulator, Vinay Prasad, who returned to the agency in August after being removed earlier.
Prasad currently heads the FDA’s Center for Biologics Evaluation and Research (CBER) and has publicly argued for tighter regulatory standards for vaccines. He has also drawn controversy for comments linking child deaths to COVID-19 vaccines.
In a letter dated February 3 and signed by Prasad, the FDA stated that its refusal to review Moderna’s application was solely due to concerns about the trial’s design. Specifically, the agency objected to Moderna’s choice of comparator, arguing that comparing the experimental shot to a standard, approved flu vaccine did not represent the “best available standard of care.”
As a result, the FDA concluded that the study did not qualify as an “adequate and well-controlled” trial under its regulatory definition.
Moderna has strongly disputed this interpretation, arguing that FDA rules do not require companies to use the most advanced or highest-dose vaccine as a comparator in clinical trials.
In a statement, Moderna CEO Stéphane Bancel said the decision undermines innovation and fails to advance shared public health goals. He emphasized that the trial design had been discussed and agreed upon with CBER before the study began.
Moderna now expects the earliest possible approval for its flu shot to come in late 2026 or 2027, pending regulatory reviews across the U.S., Europe, Canada, and Australia.
The FDA declined to comment, stating it does not discuss regulatory communications with individual companies, reported CNBC.
© 2024 Bennett, Coleman & Company Limited